GC
INDV icon

Globeflex Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Globeflex Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$923K Hold
30,280
– – 0.14% 165
2025
Q4 		$1.09M Buy
30,280
+23,164
+326% +$707K 0.17% 148
2025
Q3 		$172K Buy
+7,116
New +$149K 0.03% 315

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Globeflex Capital's INDV Position: Q1 2026 in Review

Globeflex Capital held its Indivior Pharmaceuticals (INDV) position steady in Q1 2026 at 30,280 shares worth $923K. The position accounts for 0.14% of the portfolio, ranked #165.

Globeflex Capital first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.09M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Globeflex Capital held 30,280 shares of Indivior Pharmaceuticals worth $923K as of Q1 2026.
  • Globeflex Capital left its Indivior Pharmaceuticals share count unchanged in Q1 2026.
  • Indivior Pharmaceuticals made up 0.14% of Globeflex Capital's portfolio in Q1 2026, its #165 holding.
  • Globeflex Capital first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Globeflex Capital's Indivior Pharmaceuticals position peaked at $1.09M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.